Show Notes
Could a Wnt pathway agonist match anti-VEGF therapy for DME, and what should we make of a phase 3 trial that hit its anatomic goals but missed its primary visual endpoint? Don D’Amico, MD, reviews one-year results from the phase 2b/3 BRUNELLO study of remigromig (Restoret, Merck/EyeBio), a Wnt pathway agonist, for diabetic macular edema. And Carl Regillo, MD, discusses the phase 3 LUGANO study of EYP-1901 (vorolanib, EyePoint Pharmaceuticals) for wet AMD, which missed its primary endpoint despite reducing treatment burden by 42%.
More from New Retina Radio by Eyetube
The debates at AAO Retina Subspecialty Day have a reputation for examining unresolved issues. Where did the debate on whether wet AMD tolerates fluid land? Avni Finn, MD, joined the show to recap her side of the wet AMD fluid debate—and shared what the opposite side had to argue, too. How well does she buy her own argument?
Does phacovitrectomy improve outcomes over conventional PPV for rhegmatogenous retinal detachment repair in a phakic eyes? Or does it introduce unnecessary complexity? Vaidehi Dedania, MD; Yewlin Chee, MD; and Joshua Uhr, MD, review results from a multicenter cohort study published in Ophthalmology Retina and discuss whether the study's findings have any bearing on real-world decision-making, parse generational differences regarding perceived phacovitrectomy risks, and review whether changes to technology during the course of the study may have affected the findings.
Co-hosts Justin C. Muste, MD, and David Fell, MD, are joined by Matthew Starr, MD, a vitreoretinal surgeon at the Mayo Clinic, and Timothy Xu, MD, a retina fellow at Wills Eye Hospital, to discuss retained lens fragments and secondary IOLs. They share complex cases, when to consider following patients medically, surgical techniques for removing fragments, and how to make the best secondary lens choice.
In this episode of RetinaLive focused on UNITY® VCS|CS, Matt Cunningham, MD, FASRS, welcomes Steven Yeh, MD, FASRS for a reflection on early clinical experience with the UNITY® VCS system following the first 50 cases. The discussion highlights real-world insights on surgical efficiency, fluidics stability, and intraoperative control across a range of case complexities. From seamless OR integration to advancements in 27-gauge instrumentation and laser delivery, the conversation offers practical perspectives on adoption, training, and how evolving technology can enhance surgeon confidence and patient care.
How aggressively should you manage a vitreous hemorrhage after a PVD when you can't see the retina underneath it? Barton Blackorby, MD, moderates a discussion with Matt Starr, MD, and Kyle Kovacs, MD, about a study published in Ophthalmology by Hasbolat et al examining 366 patients with PVD-related vitreous hemorrhage initially managed with observation. The panel discusses how exam technique and B-scan reliance may affect detachment detection rates, debates follow-up intervals given that most retinal detachments in the study occurred within the first 3 weeks, and shares their own thresholds for moving to early vitrectomy versus continued observation, including how they counsel patients eager for faster visual recovery.